Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 27

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 27
---
 Standards Codification (“ASC”) Topic 718, the actual value, if any, that a non-employee director may realize from the options are contingent upon the excess of the share price over the exercise price, if any, on the date the award is exercised. For a discussion of the assumptions made in the valuation of options granted in 2024, see Note 14 — “Share-based Compensation” of our audited consolidated financial statements as of and for the period ended December 31, 2024 in our Annual Report on Form 10-K for further information. |

16

TABLE OF CONTENTS

| (2) | The following table provides information on the aggregate number of outstanding share option awards for each non-employee director as of December 31, 2024. |

| Name                 |     | Aggregate Number of 
 Outstanding Options 
                 (#) |
| Simon Sturge         |     |              63,985 |
| Dr. Kara Lassen(3)   |     |                   — |
| Spike Loy(4)         |     |              18,985 |
| Catherine Moukheibir |     |              63,985 |
| Dr. Andrew Phillips  |     |              63,985 |
| Dr. Ramnik Xavier    |     |              63,985 |

| (3) | Dr. Lassen resigned from the Board effective as of December 31, 2024. |

| (4) | Pursuant to a certain agreement entered into between Mr. Loy and BVF Partners L.P. (“Partners”), Mr. Loy is obligated to transfer to Partners the economic benefit, if any, received upon the sale of the shares issuable upon the exercise of his options. |

17

TABLE OF CONTENTS

EXECUTIVE OFFICERS Biographical and other information regarding our executive officers is set forth below. There are no family relationships among any of our directors or executive officers.

| Name                         |     |              Age 
 (as of April 22) |     | Position                          |
| Dr. Jorge Santos da Silva(1) |     |               48 |     | Chief Executive Officer; Director |
| Matthias Bodenstedt          |     |               37 |     | Chief Financial Officer           |
| Dr. Kristian Reich           |     |               59 |     | Chief Scientific Officer          |

| (1) | For Dr. Santos da Silva’s biographical information, see “Information Regarding Director Nominees and Continuing Directors”